| Index | — | P/E | — | EPS (ttm) | -1.98 | Insider Own | 5.82% | Shs Outstand | 48.88M | Perf Week | 0.94% |
| Market Cap | 1.68B | Forward P/E | 12.07 | EPS next Y | 2.85 | Insider Trans | -3.53% | Shs Float | 43.41M | Perf Month | -17.00% |
| Enterprise Value | 1.77B | PEG | — | EPS next Q | 0.11 | Short Float | 12.92% | Perf Quarter | -13.93% | ||
| Income | -97.00M | P/S | 8.93 | EPS this Y | — | Short Ratio | 6.37 | Perf Half Y | 47.53% | ||
| Sales | 188.00M | P/B | — | EPS next Y | — | ROA | -38.65% | Short Interest | 5.61M | Perf YTD | 46.71% |
| Book/sh | -2.70 | P/C | 15.55 | EPS next 5Y | — | ROE | — | 52W High | 50.81 -32.93% | Perf Year | 73.10% |
| Cash/sh | 2.21 | P/FCF | — | EPS past 3/5Y | — | ROIC | -34.41% | 52W Low | 16.50 106.53% | Perf 3Y | 207.33% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | 19.79% 55.76% | Gross Margin | 90.85% | Volatility | 4.55% 5.35% | Perf 5Y | 107.86% |
| Dividend TTM | — | EV/Sales | 9.39 | EPS Y/Y TTM | — | Oper. Margin | -35.32% | ATR (14) | 1.83 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 3.41 | Sales Y/Y TTM | 100.00% | Profit Margin | -51.73% | RSI (14) | 37.82 | Recom | 2.25 |
| Dividend Gr. 3/5Y | — | Current Ratio | 3.80 | EPS Q/Q | 73.33% | SMA20 | -4.13% | Beta | 1.57 | Target Price | 56.60 |
| Payout | 0.00% | Debt/Eq | — | Sales Q/Q | 200.00% | SMA50 | -14.51% | Rel Volume | 2.10 | Prev Close | 34.36 |
| Employees | 300 | LT Debt/Eq | — | Earnings | Nov 04 | SMA200 | 9.50% | Avg Volume | 968.53K | Price | 34.08 |
| IPO Date | May 04, 2017 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -5.66% 14.02% | Net Debt/EBITDA | — | Volume | 2,037,518 | Change | -0.82% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-10-26 | Reiterated | Jefferies | Hold | $40 → $56 |
| Aug-06-26 | Reiterated | Guggenheim | Buy | $42 → $58 |
| Aug-06-26 | Reiterated | HC Wainwright & Co. | Buy | $45 → $75 |
| Jul-21-26 | Reiterated | Guggenheim | Buy | $42 |
| Jul-16-26 | Reiterated | Oppenheimer | Outperform | $31 → $50 |
| Jul-15-26 | Reiterated | Goldman Sachs | Neutral | $18 → $44 |
| May-11-26 | Reiterated | HC Wainwright & Co. | Buy | $60 → $45 |
| Apr-09-26 | Initiated | Jefferies | Buy | $40 |
| Jun-16-25 | Upgrade | HC Wainwright & Co. | Neutral → Buy | |
| Jun-13-25 | Reiterated | Goldman Sachs | Neutral | $3.00 → $16 |
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 188 | 110 | 90 | 83 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 17 | 12 | 9 | 9 | — | — | — | — | — | |
| Gross Profit | 172 | 97 | 82 | 73 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 176 | 155 | 0 | 93 | — | — | — | — | — | |
| Research and Development | 61 | 67 | 57 | 46 | — | — | — | — | — | |
| Other Operating Expense | 2 | 0 | 121 | 0 | — | — | — | — | — | |
| Operating Income | -66 | -125 | -97 | -66 | — | — | — | — | — | |
| Interest Expense | 35 | 34 | 13 | 15 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 3 | 5 | -15 | -18 | — | — | — | — | — | |
| Net Income Before Taxes | -98 | -153 | -124 | -98 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 3 | 4 | — | — | — | — | — | |
| Consolidated Net Income | -97 | -153 | -127 | -102 | — | — | — | — | — | |
| Net Income From Continuing Operations | -97 | -153 | -127 | -102 | — | — | — | — | — | |
| Net Income | -97 | -153 | -127 | -102 | — | — | — | — | — | |
| EPS (Recurring) | -1.98 | -3.19 | -2.96 | -3.55 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.98 | -3.19 | -2.96 | -3.55 | — | — | — | — | — | |
| EPS (Diluted) | -1.98 | -3.19 | -2.96 | -3.55 | — | — | — | — | — | |
| EBITDA | -70 | -136 | -94 | -60 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 9.06 | 10.22 | 5.09 | 5.24 | — | — | — | — | — | |
| Gross Margin | 91.49 | 88.18 | 91.11 | 87.95 | — | — | — | — | — | |
| Operating Margin | -35.11 | -113.64 | -107.78 | -79.52 | — | — | — | — | — | |
| Net Margin | -51.60 | -139.09 | -141.11 | -122.89 | — | — | — | — | — | |
| Shares Outstanding | 50 | 48 | 43 | 29 | — | — | — | — | — | |
| Market Capitalization | 1,704 | 1,124 | 458 | 435 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Degnan Chris | Chief Financial Officer | Oct 08 '26 | Sale | 36.69 | 2,202 | 80,791 | 4,561 | Oct 09 |
| Degnan Chris | Chief Financial Officer | Oct 08 '26 | Option Exercise | 0.00 | 4,483 | 0 | 6,763 | Oct 09 |
| Schoenberg Mark | Chief Medical Officer | Sep 08 '26 | Sale | 42.92 | 871 | 37,383 | 59,882 | Sep 09 |
| Smith Jason Drew | General Counsel | Sep 08 '26 | Sale | 42.54 | 1,519 | 64,618 | 53,141 | Sep 09 |
| Schoenberg Mark | Chief Medical Officer | Sep 07 '26 | Option Exercise | 0.00 | 1,667 | 0 | 60,753 | Sep 09 |
| Smith Jason Drew | General Counsel | Sep 07 '26 | Option Exercise | 0.00 | 3,334 | 0 | 54,660 | Sep 09 |
| Robinson James A. Jr. | Director | Aug 26 '26 | Option Exercise | 0.00 | 2,000 | 0 | 8,000 | Aug 28 |
| Schoenberg Mark | Chief Medical Officer | Aug 20 '26 | Sale | 47.05 | 60,677 | 2,854,853 | 59,086 | Aug 24 |
| Schoenberg Mark | Chief Medical Officer | Jul 09 '26 | Sale | 40.00 | 10,000 | 400,000 | 119,763 | Jul 10 |
| Schoenberg Mark | Chief Medical Officer | Jun 22 '26 | Sale | 35.01 | 10,000 | 350,100 | 129,763 | Jun 24 |
| Schoenberg Mark | Chief Medical Officer | Jun 08 '26 | Option Exercise | 0.00 | 10,000 | 0 | 144,985 | Jun 09 |
| Schoenberg Mark | Chief Medical Officer | Jun 08 '26 | Sale | 27.30 | 5,222 | 142,561 | 139,763 | Jun 09 |
| Robinson James A. Jr. | Director | May 26 '26 | Option Exercise | 0.00 | 2,000 | 0 | 6,000 | May 27 |
| Schoenberg Mark | Chief Medical Officer | May 08 '26 | Sale | 30.00 | 10,000 | 300,000 | 134,985 | May 11 |
| Robinson James A. Jr. | Director | Feb 26 '25 | Option Exercise | 0.00 | 2,000 | 0 | 4,000 | Feb 27 |